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Summary Irinotecan is a water-soluble camptothecin deriv-
ative with clinical activity against colorectal and small cell
lung cancers and is currently a standard of care therapeutic in
the treatment of colorectal cancer in combination with 5-
fluorouracil. One of the major clinical issues limiting the use
of irinotecan is gastrointestinal toxicity manifested as life-
threatening diarrhea which is reported in up to 45 % of treated
patients. The studies summarized here tested, in a rat model of
irinotecan-associated gastro-intestinal toxicity, whether a lipid
nanoparticle formulation of irinotecan, Irinophore C™, miti-
gated early-onset or late-onset diarrhea when given at doses
equivalent to unformulated irinotecan that engenders both
early- and late-onset diarrhea. Specifically, rats administered
intravenously on two consecutive days with unformulated
irinotecan at 170 mg/kg then 160 mg/kg experienced transient
early-onset diarrhea after each administration and then expe-
rienced significant late-onset diarrhea peaking 4 days after
treatment. Irinophore C™ given at the identical dose and
schedule did not elicit either early- or late-onset diarrhea in
any animals. When Irinophore C™ was combined with 5-
fluorouracil there was also no early- or late-onset diarrhea
observed. Histopathological analysis of the gastro-intestinal
tract confirmed that the effects associated with irinotecan
treatment were absent in rats given Irinophore C™ at the
identical dose. Pharmacokinetic analysis demonstrated signif-
icantly higher systemic concentrations of irinotecan in rats
given the nanoparticle formulation compared to those given
unformulated irinotecan. These results demonstrate that the
Irinophore C™ formulation is significantly less toxic than
irinotecan, used either as a single agent or in combination
with 5-fluorouracil, in a rat model of irinotecan-induced gas-
trointestinal toxicity.
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Introduction
Irinotecan is a water-soluble camptothecin derivative with
clinical activity against colorectal and small cell lung cancers
and is a standard of care therapeutic in the first-line treatment
of colorectal cancer in combination with 5-fluorouracil (5-
FU). Irinotecan also has demonstrated activity in lung [1],
gastric [2], pancreatic [3] and ovarian [4] cancers and lym-
phoma [5]. Irinotecan has a complex pharmacological profile,
and is predominantly converted by carboxylesterases to a
more active form, 7-ethyl-10-hydroxycamptothecin (SN-38).
Both irinotecan and SN-38 cause irreversible DNA damage
via stabilization of the cleavable complex that forms between
topoisomerase I and DNA during replication. While the ac-
tivities of irinotecan and SN-38 activities are dependent on
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maintenance of the lactone ring conformation, physiological
pH favors the formation of the less active carboxylate struc-
ture. This property makes irinotecan a strong candidate for
drug carrier technology, such as the lipid nanoparticle formu-
lation Irinophore C™, in which encapsulation stabilizes the
lactone ring structure and extends the circulation lifetime of
both irinotecan and SN-38 [6–8]. The pharmacokinetics and
biodistribution of this formulation in tumor-free and tumor-
bearing mice has been reported previously [7–10]. Irinophore
C™ achieves significantly enhanced anticancer efficacy, com-
pared to free irinotecan, in a number of human xenograft
tumor models [7, 9, 10].
Increasing the therapeutic activity of irinotecan, as can be
achieved using nanoparticulate drug carriers, will only be
clinically important if the toxicities of the drug are comparable
or reduced. Patients treated with irinotecan-based chemother-
apy are at high risk for developing gastrointestinal (GI) mu-
cositis, manifested as severe diarrhea, which occurs in 45 to
80 % of cases [11–13]. This side effect often leads to delay in
treatment, dose reductions, or treatment cessation; all of which
can compromise treatment outcomes. Two specific forms of
GI toxicity are associated with irinotecan therapy. The first is
early onset diarrhea associated with cholinergic symptoms
such as cramps, diarrhea, salivation, visual disturbances and
lacrimation [11]. A more insidious toxicity is late onset diar-
rhea, which manifests at the third day post-treatment and may
be life threatening [12]. One assessment of irinotecan induced
late onset diarrhea [11] showed that 82 % of patients experi-
enced this toxicity while others report incidence of 50–80 %
[12]. Acute toxicity assessments in mice and rats have sug-
gested that Irinophore C™ may be 2- to 3-fold less toxic than
free irinotecan based on clinical observations, behavioral
changes and weight loss (unpublished observations). These
preliminary studies, however, did not address the specific
problem of late onset gastrointestinal toxicity that is most
relevant in the clinical setting. Furthermore, since results from
our lab that have shown higher plasma concentrations of SN-
38 over extended times when irinotecan is administered as
Irinophore C™ [8], it might be expected that Irinophore C™
treatment could increase the severity of late onset gastrointes-
tinal toxicity compared to free irinotecan.
In the studies reported here, we compared the ability of
Irinophore C™ and irinotecan to illicit late onset diarrhea
in a rat model designed to mimic the clinical presentation
of this GI toxicity (adapted from Trifan et al. [14]).
Further, we have also compared Irinophore C™ and
irinotecan when co-administered with 5-FU as is mostly
commonly used for the treatment of colorectal cancer. The
results show that significant adverse GI toxicities, specif-
ically both early and late onset diarrhea, associated with
irinotecan or irinotecan plus 5-FU treatment are not ob-





Newark, NJ) and cholesterol (Avanti Polar Lipids, Alabaster,
AL), in a DSPC/cholesterol ratio of 55/45 (mol/mol), were
used as follows: lipids were dissolved at the DSPC/cholesterol
55/45 M ratio in 2,030 mL of anhydrous ethanol with heating
to 40 °C, sterile filtered and then mixed with 21,000 mL of a
degassed 300 mM copper sulphate solution. During this initial
dispersion step, the ethanol lipid solution was maintained at
~50 °C and the copper sulphate was maintained at ~70 °C.
This lipid suspension was concentrated to a final volume of
800 mL using an ultrafiltration hollow fibre cartridge system
(GE Healthcare) then extruded through stacked 0.2 and
0.1 μm filters in an 800 mL thermobarrel extruder
(Extruder™, Northern lipids, Vancouver, BC, Canada). The
resultant nanoparticles had a mean diameter of 90–115 nm as
determined by Phase Analysis Light Scattering methods
(ZetaPALS, Brookhaven Instruments Corp., Holtsville, NY).
To remove ethanol, the external buffer was exchanged with a
300 mM copper sulphate solution using an ultrafiltration
hollow fibre column (GE Healthcare). Subsequently, the ex-
ternal buffer was exchanged to a sucrose/HEPES/EDTA buff-
er pH 7.4 (300 mM sucrose, 20 mM HEPES, 15 mM EDTA)
and diluted to a final volume of 3578.0 mL to allow for
irinotecan drug loading.
Loading of irinotecan into preformed DSPC/cholesterol
nanoparticles
Prior to drug loading, the cholesterol concentration was quan-
tified by an HPLC method and the measured cholesterol
concentration (13.26 mg/mL) was used to determine the re-
quired amounts of A23187 and irinotecan to be added to the
nanoparticles. A23187 is a divalent metal ionophore that is
used to facilitate the loading of irinotecan into the Irinophore
C™ nanoparticle using the procedure described below and in
[6]. HPLC analysis of cholesterol was performed using a C18
Symmetry shield column (4.6 × 75 mm, 3.5 μm particle size,
Waters Mississauga ON) and an isocratic elution of 92 %
methanol and 8 % of water. Sample preparation was done by
extraction using CHCl3:methanol (1:1, vol:vol) solvent, evap-
orating the organic layer and reconstituting the residue with
100 %methanol. (+)−4-cholesTen-3-one (3ONE) was used as
internal standard. Samples (20 μL) were injected onto the
column and eluted at a flow rate of 1.5 mL/min. Sample
temperature was maintained at 15 °C, column temperature at
30 °C. Cholesterol was measured based on the integration of
the peak area using a Waters 996 photodiode array (PDA)
detector (Waters, Mississauga, ON) set with wavelength of
202.8 nm. The retention time for cholesterol was 17 min and
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(+)−4-cholesTen-3-one (3ONE) was 13 min. Measurements
were done in triplicate.
Based on the cholesterol concentration determined as de-
scribed above, 14.52 mL of A23187 (calcimycin; Sigma,
Oakville, ON, Canada; 2 mg/mL (3.8 mM) solution in
100 % ethanol) was pre-incubated with the nanoparticle sus-
pension (at 1.748 μg/mg cholesterol) at 50 °C for 30 min.
Subsequently, 575.4 mL of irinotecan hydrochloride
trihydrate (Sichuan Guanghan Biotech) solution composed
of irinotecan (25.6 mg/mL), sorbitol (45 mg/mL) and lactic
acid (0.09 mg/mL) in water, was added to the nanoparticle
suspension (at a drug-to-lipid ratio of 0.2:1 (mol:mol) and
drug loading into the nanoparticles was allowed to proceed
at 50 °C for 60 min.
After irinotecan loading, the solution was cooled to
40 °C, concentrated by tangential flow to 950 mL, buffer
exchanged with glycerine/TRIS (10 % w/w glycerine/
0.435 % w/w (~40 mM) TRIS) using an ultrafiltration
hollow fibre column (GE Healthcare) and quantified for
irinotecan drug concentration. Because fluorescence mea-
surements are more sensitive than UV measurements for
irinotecan, UV detection of irinotecan for quantification
purposes was not preferred. Therefore, irinotecan concen-
tration in the product concentrate was measured using
HPLC set-up with a RP C18 Symmetry shield column
(size 250 × 4.6 mm, particle size 3.5 μm) and C18
Symmetry shield guard column (Waters, Mississauga,
ON). An isocratic elution of 78 % of mobile phase A
and 22 % of mobile phase B was used with mobile phase
A composed of 75 mM ammonium acetate and 7.5 mM
tetrabutylammonium bromide adjusted to pH=6.4 with
glacial acetic acid and mobile phase B of 100 % acetoni-
trile. An irinotecan standard curve was prepared by serial
dilution in 4 % acidified methanol. Sample dilutions were
also made in 4 % acidified methanol. Samples (10 μL)
were injected onto the column and eluted at a flow rate of
1 mL/min. Prior to injection all standards and samples
were maintained at 4 °C. Column temperature was set at
35 °C. Irinotecan was quantified based on the standard
using a Waters 2475 multi-wavelength fluorescence de-
tector (Waters, Mississauga, ON) set at 370 nm excitation
and 425 nm emission. The retention time for irinotecan
was 12 min. Measurements were done in triplicate. The
product concentrate was then diluted to 407 mL with the
glycerine/TRIS buffer to achieve a final irinotecan con-
centration of 11 mg/mL. The resultant Irinophore C™
product was aseptically sterile filtered and filled into
10 mL vials (5 mL per vial). Vials were frozen at−80 °C
until required. It should be noted that this large scale
batch of approx 400 mL of final sterile Irinophore C™
product was generated to support a wide variety of studies
including those described here as well as other product
stability and GLP related studies.
Animals
Female Sprague–Dawley rats were purchased from Harlan
Laboratories, Inc. (Indianapolis, IN). Rats were housed in
pairs and maintained in sterilized ventilated filter-topped
cages in a specific pathogen-free barrier facility (Animal
Resource Center (ARC) at the British Columbia Cancer
Agency’s Vancouver Cancer Research Centre); irradiated
food and chlorinated treated water were given ad libitum.
Animals were acclimatized to their holding room for a mini-
mum of 5 days prior to initiating the studies. Sentinel animals
from holding rooms were tested for common pathogens, and
results were negative for the duration of this experiment and
for a minimum of 18months prior. All studies were completed
under an animal care protocol approved by the Institutional
Animal Care Committee (IACC). The IACC for studies con-
ducted at ARC is operated by the University of British
Columbia and operates in accordance to the Canadian
Council of Animal Care (CCAC). The ARC is a CCAC
audited facility.
Establishment of late onset diarrhea model
The model of irinotecan-induced diarrhea used here was mod-
ified from that described by Trifan et al. [14]. To establish this
model in our facility, groups of rats (n=2) were treated i.v. (by
the tail vein) on two consecutive days with 160, 170 or
180 mg irinotecan/kg or at 170 mg/kg on day 1 and then at
160 mg/kg on day 2. Irinotecan was infused using a syringe
pump at a maximal infusion rate of 2.5 mL/min/kg; a total
volume of approximately 8 mL was administered over a
15 min time period. A group of two rats was given 5 %
dextrose in water (D5W) by infusion to establish that the
infusion rate and volume could be safely given. Blinded
observations were conducted daily until day 10 to confirm
recovery from the adverse effects caused by treatment.
Diarrhea was scored twice per day (approx. 7 am and 4 pm)
using the following scale: 0 (normal stool or absent), 1 (slight
wet/soft stool), 2 (more than slight but less than moderate
diarrhea), 3 (moderate diarrhea: wet and unformed stool with
moderate perianal staining of the coat), 4 (moderate diarrhea;
severe anal staining) and 5 (severe diarrhea: watery stool with
severe perianal staining of the coat). Assessments were con-
ducted on fresh visible stool samples and cages were changed
daily. Body weights and clinical signs were also observed and
recorded daily. Clinical signs assessed in addition to diarrhea
included: fur/skin-related signs, behavioural or motor
function-related signs, whole body signs, limb or paralysis-
related signs, breathing-related signs and bodily function-
related signs. These clinical signs were assigned scores of 0
to 5. Any rat having an individual observation with severity
score of 5, or a combined observation score of 10, was
euthanized by CO2 asphyxiation (except where noted). All
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scoring was conducted under a Standard Operating Procedure
(SOP) and the observer trained under this SOP was blinded to
the study. A single observer was used to record data through
the course of the experiment.
Histopathology assessment
GI tissue including the duodenum, jejunum, ileum and the
colon were collected 3 days after the last dosing day.
Approximately 2 in. of each section of the intestinal tract were
excised and any contents were gently removed by flushing
with phosphate-buffered saline (PBS). Each section was then
cut transversely into 2 halves and then one of the halves was
cut longitudinally. Both tissue pieces were rinsed in PBS and
then fixed in Molecular Fixative (Somagen, Edmonton, AB).
Fixed tissues were sent to Wax-it Histology Services Inc.
(Vancouver, BC, Canada) and embedded in paraffin. Cross
sections of the intestinal tract (5 μm)were cut and mounted on
slides and stained with hematoxylin and eosin (H&E). Slides
were then sent to Animal Pathology Services Ltd. (Alberta,
Canada) and were examined by a board certified veterinary
pathologist. The pathologist was blinded to the experimental
group assignments of each animal. Slides were scanned with
the Panoramic MIDI (3DHISTECH, Budapest, Hungary) and
images created using Panoramic Viewer from 3DHISTECH,
version 1.5.
Comparison of irinotecan with Irinophore C™ in a late onset
diarrhea model
Groups of 12 female Sprague–Dawley rats were administered
(by intravenous infusion as described above) with D5W,
irinotecan or Irinophore C™ at 170 mg/kg (day 1) and
160 mg/kg (day 2). Diarrhea and clinical observations were
scored daily for 10 days post administration. Four animals
from each treatment group were sacrificed 3 days post admin-
istration for histological assessment of intestine and colon.
Comparison of irinotecan plus 5-FU versus Irinophore C™
plus 5-FU in a late onset diarrhea model
Groups of 8 female Sprague–Dawley rats were treated with a
combination of irinotecan or Irinophore C™ at 150 mg/kg by
intravenous infusion on day 1 and day 2 and with 5-FU at
15 mg/kg by slow bolus intravenous injections on day 1 and
day 2. The administration of 5-FU was performed immediate-
ly before the administration of irinotecan or Irinophore C™.
In these studies, rats were observed daily for 20 days for
clinical assessment and scoring of diarrhea as described
above. Control groups consisted of each test article or saline
administered (as described above) as a single agent. Body
weights, in-life observation scores and diarrhea assessments
were individually subjected to a 2-way mixed model ANOVA
with treatment condition as a between subject factor and time
(days) as the within-subject factor. Between group differences
were analyzed using Bonferroni post hoc analysis.
Pharmacokinetic study and bioanalysis
For the pharmacokinetic studies, the rats were administered as
described above using doses of 170 mg/kg on day 1 and
160 mg/kg on day 2. Blood was collected by saphenous vein
or by cardiac puncture at the final time point. Blood was
collected into EDTA-containing Microtainer® tubes and the
plasma was recovered after centrifugation.
For sample extraction, 150 μL of 4 % acetic acid in
methanol was added to aliquots of 50 μL plasma. This was
centrifuged for 15 min at 4 °C and 13,500 rpm (17,110 rcf).
Following centrifugation, 100 μL supernatant was transferred
to tubes containing 1,400 μL acetic acid in water. This was
then mixed on a vortex mixer and transferred to solid phase
extraction wells using moderate vacuum. Analytes were elut-
ed with 400 μL 4% acetic acid in methanol then evaporated to
dryness. Sample residues were reconstituted into 150 μL of
100 ng/mL camptothecin (Sigma; internal standard) in 4 %
acetic acid in acetonitrile. 2 μL of reconstituted samples were
injected onto UPLC-MS/MS for analysis. Standard curves
were generated using plasma samples spiked with irinotecan
HCl (Sigma).
Analysis was performed on a Waters Acquity UPLC sys-
tem using a Waters Acquity BEH C18 1.7 μm, 2.1 mm ×
50 mm column maintained at 30 °C and Waters TQD and
PDA detectors. Mobile phase Awas water with 0.1 % formic
acid. Mobile phase B was acetonitrile with 0.1 % formic acid.
A gradient of 5 to 70 % B in 2.5 min, wash at 98 % B for
0.5 min, back to initial conditions in 1.3 min was used.
Pharmacokinetic parameters were estimated using a non-
compartmental analysis with Phoenix WinNonlin (v. 6.2).
Results
Establishment of late onset diarrhea model
The model of camptothecin-induced late onset diarrhea used
here was adapted from that described previously [14]. To
assess GI toxicities associated with D5W (control) or
irinotecan administration, female Sprague–Dawley rats had
diarrhea scored twice daily as described in the Methods.
Scores were tabulated and averaged for the different treatment
dosages of 160 mg/kg (Fig. 1), 170 mg/kg (Fig. 1) or
180 mg/kg on day 1 and day 2 (not shown). The D5W control
treatment rats did not exhibit any signs of diarrhea, having an
average group score of 0 throughout the study (data not
shown). Rats dosed with irinotecan at 160 mg/kg on two
1074 Invest New Drugs (2014) 32:1071–1082
consecutive days exhibited partial early-onset diarrhea, but no
late-onset diarrhea. This is shown by the high GI toxicity score
on day 1.5 (the afternoon measurement of day 1 treatment)
with a mean score of 3, a very low GI toxicity score of <0.5
after the second dose (day 2.5; afternoon measurement of day
2) and negligible GI toxicity (scores >1.0) observed over the
remaining time course. Rats given irinotecan at the higher
dose of 170 mg/kg exhibited early onset diarrhea on both
administrations days (days 1.5 and 2.5, Fig. 1). In the absence
of any further treatment, animals given 170 mg/kg irinotecan
exhibited signs of late stage diarrhea starting on day 4 and
persisting until day 7. These signs included GI toxicity scores
of between 1 and 3 through day 9 (Fig. 1) and clinical
observation scores ranging from 5 to 7.5 through day 7 (not
shown). This second toxicity phase was associated with more
severe effects where mean body weight loss of almost 10 %
was noted on days 5 and 6 of the experiment (data not shown).
By the end of this experiment the animals had almost
completely recovered with the exception for some mild por-
phyrin staining on the neck area.
These preliminary studies demonstrated that two consecu-
tive doses of 160 mg/kg irinotecan were not sufficient to cause
late onset diarrhea and while two consecutive doses of
irinotecan at 170 mg/kg did induce late onset diarrhea, how-
ever these animals almost reached humane endpoints speci-
fied in the protocol. As indicated, these preliminary studies
also assessed toxicity associated with two consecutive dose of
180 mg/kg irinotecan. This dose resulted in toxicities severe
enough to warrant euthanasia (data not shown).
Irinotecan compared with Irinophore C™ in a late onset
diarrhea model
Based on the studies summarized above, subsequent studies
used a treatment schedule consisting of 170 mg/kg adminis-
tered on day 1 and 160 mg/kg on day 2. Rats were given either
irinotecan or Irinophore C™ with inclusion of additional
animals for histopathological assessments of the GI tract at
the peak of late onset GI toxicity. Figure 2 summarizes the
results for GI toxicity (Fig. 2a), clinical observations (Fig. 2b)
and body weights (Fig. 2c).
Consistent with the model development work described
above, administration of irinotecan resulted in early onset of
GI toxicity with moderate diarrhea consisting of wet and
unformed stool with moderate perianal staining of the coat.
Average GI toxicity scores of 2.8 were recorded following the
first injection and 2.7 following the second injection; these
were observed in the afternoons of each infusion day (Fig. 2a).
Late onset diarrhea was also observed in these animals,
reaching a peak with an average GI toxicity score of 1.2 on
day 5, approximately 72 h after the final dose of irinotecan.
Fig. 1 GI toxicity (diarrhea) scores for rats administered with irinotecan at
either 160 mg/kg on days 1 and 2 or at 170 mg/kg on days 1 and 2 .
Administrations are indicated by arrows. Symbols represent the means±
standard error of 3 rats in the irinotecan 160 mg/kg group and 2 rats in the
irinotecan 170 mg/kg group. All data was collected in blinded fashion
Fig. 2 GI toxicity (diarrhea) score (a), total clinical observation scores
(b) and bodyweight change as a percentage of weight on day 1 (c) for rats
given D5W (equal volume to irinotecan) (●), irinotecan or Irinophore
C™ at 170 mg/kg on day 1 and 160 mg day 2. Administrations are
indicated by arrows. Symbols represent the means±standard error of 4
rats. All data was collected in blinded fashion
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Rats given irinotecan also exhibited several clinical observa-
tions including abnormal gait, shaking and twitching, hunched
posture while sitting and marked porphyrin staining on the
neck and nose area. In this group mean clinical scores of 10
were observed in animals during the infusion days of the
experiment and in the early onset of diarrhea phase. In some
animals scores transiently in excess of 10 were noted, but after
consultation with the clinical veterinarian and based on the
preliminary study indicating that acute toxicities resolve rap-
idly, these animals were maintained on study. Scores subse-
quently decreased to approximately 2, but then peaked again
during the late stage diarrhea phase (days 4–7) with mean
clinical scores of 6–7 (Fig. 2b). By the end of the study (day
10) these animals had completely recovered. GI toxicities
noted in the irinotecan treated animals were associated with
mean body weight losses of just over 10 % on day 5 of the
study (Fig. 2c).
When irinotecan was administered as the lipid nanoparticle
formulation Irinophore C™ (Fig. 2), no GI toxicity was ob-
served at any time during the study. Both early and late onset
diarrhea were absent (Fig. 2a; p<0.001, as compared with
irinotecan treated animals). Rats given Irinophore C™ scored
identical to, and were not statistically different from, the D5W
control in terms of GI toxicity (Fig. 2a). However, adminis-
tration of Irinophore C™ did result in small, but measurable,
changes in clinical observations (Fig. 2b) and a 7 % loss in
mean body weight (day 3) which was almost completely
resolved by day 10 (Fig. 2c). Animals in the D5W control
group did not show any signs of stress related to the infusion
or handling. In-life clinical observation scores were 0 in these
animals.
Necropsies were performed on all animals, with one group
of animals euthanized on day 5 while the remaining animals
were euthanized at the end of the study (day 10). No unusual
findings were noted in animals given infusions with D5W. On
day 5, the irinotecan treated rats had major GI abnormalities
including distension, inflammation and swelling of the intes-
tines and stomach. In contrast, those rats given Irinophore C™
only exhibited slightly inflamed intestines and had no other
findings. All animals appeared normal on gross necropsy at
the end of the study, 8 days after the last dose was given.
GI tissue including parts of the duodenum, jejunum,
ileum and the colon were collected from rats on day 5.
Approximately 2 in. of each section of the intestinal tract
were excised and any contents gently removed by washing
and prepared for histological assessments as described in
the Methods. H&E stained slides were provided to a board
certified veterinarian pathologist who was blinded to the
groups. Specific observations by the pathologist were re-
corded and these have been summarized in Table 1. For the
irinotecan group, severity evaluations are provided in
Table 2 and representative images of colon and duodenum
are shown in Fig. 3.
In the D5W control group, one animal had moderate
changes in the ileum section of the intestine with loss of the
epithelial lining of the villi, an increase in the number of
mononuclear inflammatory cells in the villi and focal areas
of congestion of the capillaries at the tips of the villi. In the
longitudinal section there was additional local area of hemor-
rhage in the serosa and congestion of villar capillaries was
more general. In these animals, the changes were considered
to be “mild” to “very mild”. All other control animals were
microscopically normal. Rats given irinotecan had changes in
the intestine and the colon that, in general, consisted of vas-
cular congestion and local edema through to alteration of the
mucosal architecture with shortening and fusion of villi, loss
of villar epithelium with flattening of the remaining epithelial
cells and wide dilation of the villar lymphatics. Inflammation
was not associated with these lesions. Qualitatively, such
changes were similar in all affected animals, but quantitatively
the severity varied considerably between individuals. Detailed
histopathological observations for the irinotecan-treated ani-
mals are provided in Table 1 with a summary in Table 2. In
rats given Irinophore C™, three of four rats were found to be
microscopically normal on day 5. One rat in this group had
dilated crypts in the duodenum, but was otherwise microscop-
ically normal. This was discussed with the veterinarian pa-
thologist after the study was unblinded and it was concluded
that theses change did not match those seen in any of the rats
given irinotecan; suggesting that the findings in this animal’s
duodenum were incidental and unrelated to the study
treatment.
Comparison of Irinotecan plus 5-FU versus Irinophore C™
plus 5-FU in a late onset diarrhea model
Damage to the intestinal mucosa is a sequela of both 5-FU and
irinotecan administration, leading to epithelia loss and subse-
quent increased fluid volume leaving the small bowel [15].
This in turn leads to diarrhea, the severity of which is ampli-
fied when the two agents are used in a combination therapy
regimen. It is possible that the benefits in terms of reduced GI
toxicity noted when irinotecan is given as the Irinophore C™
nanoparticle formulation could be lost when the formulation is
combined with 5-FU. To test this, we also assessed the GI
toxicity of 5-FU when used in combination with either
irinotecan or Irinophore C™.
The 5-FU dose of 15 mg/kg on each treatment day was
determined in a preliminary dose-range finding study in which
irinotecan was given at 150 mg/kg on day 1 and day 2 and 5-
FU given on each day at doses of 10, 15, 20 or 25 mg/kg. This
study (data not shown) indicated that the 15 mg/kg dose of 5-
FU, used in combination with irinotecan at 150 mg/kg on day
1 and day 2, elicited both early and late onset diarrhea and
could be conducted within humane endpoints. The lower
(10 mg/kg) dose of 5-FU did not elicit late onset diarrhea in
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Table 1 Histopathological findings in rats treated with D5W, irinotecan or Irinophore C™
Animal # Organ Observations
D5W control






#28 Duodenum Microscopically normal
Jejunum Microscopically normal
Ileum Cross section: Loss of the epithelial lining of the villi with an increase
in the number of mononuclear inflammatory cells in the villi
and focal areas of congestion of the capillaries at the tips
of the villi. Longitudinal section: local hemorrhage in the serosa





# 29 Duodenum Microscopically normal
Jejunum Dilation of the lymphatics of the mucosa, particularly
in the villi. Edematous lamina propria without increase





# 30 Duodenum* Alteration of the mucosal architecture: shortening and fusion
of villi, loss of villar epithelium. Flattening of the remaining epithelial
cells, dilation of the villar lymphatics, and edema of the mucosal
lamina propria. Congested capillaries.




Colon—transverse Cross section: A number of crypts throughout the mucosa are widely
dilated, with general secretion of fluid into the lumen. Flattened
crypt epithelium. Mild edema of the lamina propria. Longitudinal
section: epithelial damage with vascular reaction at several levels
of the GI tract without associated inflammation.
# 31 Duodenum There is congestion of some of the capillaries of villi, and edema
of the lamina propria of such villi, especially at the tips.
Jejunum Changes in the ileum similar to those in the duodenum
Ileum Cross section: Shortening and fusion of villi, loss of villar epithelium
with flattening of the remaining epithelial cells, wide dilation
of the villar lymphatics, and edema of the mucosal lamina propria.
Multiple instances of several villi to be fused with a single
overarching layer of epithelial cells. Longitudinal section: flattened




# 32 Duodenum Complete disorganization of the normal architecture. Loss of villi
and collapse of villar mucosa. The resulting mucosal lining consists
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combination with irinotecan and both higher doses of 5-FU
(20 and 25 mg/kg) were not tolerated. Therefore, the combi-
nation of 150 mg/kg irinotecan plus 15 mg/kg 5-FU, both
given on day 1 and day 2, was selected for the comparative
study of irinotecan and Irinophore C™.
Similar to the studies described above evaluating single
agent irinotecan or Irinophore C™, these treatments were
associated with reactions (twitching, shaking, poor gait and
respiratory issues) that started 2–3 min after the onset of the
infusion, continued for the duration of the 15min infusion, but
resolved within 1 h. GI toxicity and clinical observation
scores, along with % change in body weight for the in-life
portion of these studies, are summarized in Fig. 4. Rats given
vehicle control (saline) on day 1 and day 2 did not experience
any signs of GI toxicity (Fig. 4a) or changes in clinical
observations (Fig. 4b) at any time during the study.
Similarly, animals given 5-FU alone at 15 mg/kg showed no
signs of GI toxicity or any changes in clinical observations
(data not shown). The GI toxicity data indicated that a com-
bination of irinotecan (150 mg/kg on day 1 and day 2) plus 5-
FU (15 mg/kg on day 1 and day 2) was not well tolerated as
reflected by a weight loss nadir of−7.7 %, (Table 3), signifi-
cant clinical observation scores on days 7–9 and both early
onset and late onset diarrhea (Fig. 4a). In marked contrast,
treatment with Irinophore C™ (150 mg/kg on day 1 and day
2) in combination with 5-FU (15 mg/kg on day 1 and day 2)
had no significant GI toxicity scores (Fig. 4a). These GI
toxicity scores of the irinotecan plus 5-FU group and of the
Irinophore C™ plus 5-FU group, given at the equivalent dose
and schedule, were significantly different at both early onset
timepoints (days 1 and 2; p<0.001) and late onset timepoints
(days 5.5–7.5; p<0.05). There was, however, significant
weight loss in the Irinophore C™ plus 5-FU group (nadir of
−6.6 % on day 4; Table 3) and the clinical observation scores
for this group were comparable to the irinotecan plus 5-FU
group on days 3–4.
On necropsy, animals given irinotecan in combination with
5-FU had enlarged cervical and mesenteric lymph nodes. The
latter were red in color. The spleen and liver exhibited a
granular appearance, the intestines appeared slightly inflamed,
thymus was small and partially reddish and the lungs appeared
dark. Necropsy observations for these animals indicated a
Table 1 (continued)
Animal # Organ Observations
of a series of widely dilated lymphatics from the villar cores mixed













# 35 Duodenum There are two widely dilated crypts. One of these contains a large
protein cast within which there are colonies of short rod shaped bacteria.
Jejunum Microscopically normal
Ileum Microscopically normal (large numbers of filamentous bacteria in lumen)
Colon—ascending Microscopically normal (large numbers of filamentous bacteria in lumen)
Colon—descending Microscopically normal
Colon—transverse Microscopically normal
Table 2 Histological lesion and severity summary for the irinotecan-
treated rats. There were no lesions observed in the animals treated with
Irinophore C™
Animal # Group Duodenum Jejunum Ileum Colon
29 Irinotecan +*
30 Irinotecan +++ ++ ++
31 Irinotecan + + +++
32 Irinotecan +++
* +, ++ and +++ indicate severity, from least to most severe
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wide range of toxicities associated with the combination of 5-
FU plus irinotecan that were not present in animals given
either irinotecan or 5-FU as single agents. Necropsy observa-
tions of all animals given Irinophore C™ in combination with
5-FU at the end of the study suggested only minor changes: a
marbled appearance on the kidney, swollen glands in the
urogenital area of one animal and a malformed spleen in the
same animal. Importantly, the exacerbated necropsy findings
associated with the combination of 5-FU and irinotecan were
not seen when 5-FU was combined with Irinophore C™. The
ability of Irinophore C™ to abrogate the early and late onset
toxicities elicited by irinotecan when the drug is given at
equivalent doses in the free form, in the presence and absence
of 5-FU, provides evidence suggesting that this dose-limiting
toxicity may be reduced or eliminated in patients treated with
this lipid nanoparticle formulation of irinotecan.
Pharmacokinetics of Irinotecan and Irinophore C™
To complete these studies, an evaluation of the pharmacoki-
netics of irinotecan and Irinophore C™was completed in rats.
Irinotecan was administered at a dose and schedule that elic-
ited both early and late onset diarrhea and Irinophore CTMwas
given at the equivalent dose and schedule (intravenous infu-
sions at a dose of 170mg/kg on day 1 and at 160mg/kg on day
2). Plasma concentrations of irinotecan were measured up to
96 h after the start of dosing and pharmacokinetic parameters
estimated using a non-compartmental analysis.
When irinotecan was administered intravenously as the
free drug, it was rapidly cleared from the circulation of rats
with an estimated elimination half-life (T½) of 4.6 h, clearance
(CL) of 873.0 mL/h/kg, a total AUC (AUC0-∞) of 378 μg h/
mL and a volume of distribution (Vd) of 5820.1 mL/kg
(Table 4). Area-under-the-curve and maximum plasma con-
centrations (Cmax) values for irinotecan were similar on day 1
(171.5 μg h/mL for AUC0–24) and day 2 (203.4 μg h/mL for
AUC24–48) after the administration of free drug (Table 4),
indicating negligible accumulation of drug on the second
administration. This is consistent with the observation that
the mean plasma concentrations of irinotecan 24 h after the
day 1 administration of the free drug, 0.06μg/mL, represented
only 0.2 % of the concentration immediately after the day 1
administration (30 μg/mL) and only 0.3 % of the plasma
concentration immediately after the day 2 infusion (22.1 μg/
mL).
When irinotecan was administered intravenously in the
Irinophore C™ nanoparticle formulation, the distribution
and removal of the drug from the circulation was dramatically
slower than that observed with free drug (Fig. 5). Specifically,
the T½ was increased to 9.1 h, CL decreased by approximately
229-fold to 3.8 mL/h/kg, the total AUC corresponding in-
creased by 229-fold up to 86,630 μg h/mL and the Vd de-
creased 116-fold to 50.02 mL/kg (Table 4). These changes
were reflected by dramatic increases in the observed Cmax of
irinotecan in the plasma, 3,197 and 3,172 μg/mL on day 1 and
2, respectively. This represents 106- and 143-fold increases
over the corresponding Cmax values observed after the admin-
istration of free drug (Table 4). Although the Cmax values after
day 1 and day 2 administrations, 3,197 and 3,172 μg/mL
respectively, were very similar, when the elimination curves
were analyzed separately, the AUC values for irinotecan given
as Irinophore C™ were significantly different on day 1
(33,083 μg h/mL for AUC0–24) and day 2 (42,548 μg h/mL
for AUC24–48) (Table 4). This is consistent with the observa-
tion that the mean plasma concentrations of irinotecan 24 h
after the day 1 administration of the Irinophore C™ nanopar-
ticle, 369.6 μg/mL, represented 11.6 % of the concentration
immediately after the day 1 administration (3,197 μg/mL) and
11.6 % of the Cmax concentration immediately after the day 2
infusion (3,172 μg/mL). These observations indicate that the
Fig. 3 Hematoxylin and eosin
stained sections of colon (a–c)
and small intestine (duodenum;
d–f) from rats given D5W (a, d),
irinotecan (b, e) or Irinophore C™
(c, f). All images obtained with
10X objective. Note the
shortening and fusion of villi, loss
of villar epithelium with
flattening of remaining epithelia
cells, dilation of villar lymphatics,
edema of mucosal lamina propria
and congestion of capillaries in
irinotecan-treated rat sections (b,
e). Bars indicate 200 μm
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circulation lifetime of Irinophore C™ is sufficiently long that
it is not entirely cleared 24 h after IV infusion and further daily
administrations additively increase the systemic exposure to
total irinotecan.
Discussion
Late onset diarrhea is a major dose-limiting toxicity of
irinotecan treatment in the clinic. A model of late onset diar-
rhea has been described previously [14]; a model in which
diarrhea started approximately 48 h after the final dose of
irinotecan and became more severe by day 5 before resolving
by day 7–8. Although the doses and dose schedule of
irinotecan needed to elicit early and late onset diarrhea in rats
are different from those used therapeutically in humans, in
both rat models and in humans early diarrhea occurs within
24 h of irinotecan administration and late diarrhea occurs more
than 24 h after drug administration. We sought to reproduce
this model in Sprague–Dawley rats and determine whether
irinotecan-based GI toxicity was changed when the drug was
administered as Irinophore C™. In the present study a repro-
ducible model of late onset diarrhea is described however the
doses needed to achieve late onset diarrhea were different than
Fig. 4 GI toxicity (diarrhea) score (a), total clinical observation scores (b)
and body weight change as a percentage of weight on day 1 (c) for rats
given saline (●), irinotecan at 150 mg/kg on days 1 and 2 plus 5-FU at
15 mg/kg days 1 and 2 or Irinophore C™ at 150 mg/kg days 1 and 2
plus 5-FU at 15 mg/kg on days 1 and 2 . Administrations are indicated
by arrows. Symbols represent the means (±standard error) of 7–8 rats
Table 3 Weight loss (average at
nadir) and survival by study end
for rats given saline, 5-FU,
irinotecan, Irinophore C™,
irinotecan plus 5-FU or
Irinophore C™ plus 5-FU
Dose (mg/kg) on day 1 & day 2 Weight loss (%) at Nadir Nadir loss (day) Survival
Irinotecan Irinophore C™ 5-FU
– – – −0.7 3 100 % (8/8)
– – 15 −1.8 2 100 % (8/8)
150 – – −7.5 5 100 % (8/8)
– 150 – −5.7 3 100 % (8/8)
150 – 15 −7.7 7 87 % (7/8)
– 150 15 −6.6 4 100 % (8/8)
Table 4 Summary pharmacokinetic parameters for total irinotecan in rats
after each administration of either irinotecan or Irinophore C™ at
170 mg/kg on day 1 then 160 mg/kg on day 2
Parameter Irinotecan Irinophore C
Day 1 Day 2 Day 1 Day 2
Dose (mg/kg) 170 160 170 160
Cmax observed (μg/mL) 30.0 22.1 3,197 3,172
T½ (Elim.)* (h) 4.6 9.1
AUC0–24 (μg h/mL) 171.5 – 33,083 –
AUC24–48 (μg h/mL) – 203.4 – 42,548
AUC0-∞ (μg h/mL) 378 86,630
Vd** (mL/kg) 5820.1 50.02
CL** (mL/h/kg) 873.0 3.8
* Estimated from the clearance curves after the second day of dosing, i.e.,
from 24 h to 72 h (irinotecan) or 96 h (Irinophore C™) after the study start
** Calculated based on AUC0-∞
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those reported by Trifan et al. [14]. In this study, irinotecan
was dosed at 170 mg/kg on day 1 followed by 160 mg/kg on
day 2. Importantly, very small increases in the dose of free
irinotecan were sufficient to produce toxicities warranting
euthanasia.
Using this model of GI toxicity, Irinophore C™, when
given at equivalent doses to the maximum tolerated dose of
free irinotecan, exhibited no GI toxicity. Evidence to support
this included direct assessments of diarrhea (GI toxicity score)
as well as clinical observations and weight of animals given
irinotecan or Irinophore C™ as compared to animals given
saline. For example, there were no measurable increases in GI
toxicity seen in rats given Irinophore C™ whereas animals
given irinotecan exhibited acute toxicity scores of almost 3
and late onset scores of greater than 1 (see Fig. 2). The absence
of GI toxicity in rats given Irinophore C™ was corroborated
by histological evaluation of the intestines; rats given free
irinotecan exhibited significant histological changes while
there were only minor observations in rats treated with
Irinophore C™. It should be noted that Irinophore C™ did
cause some toxicities in rats at the doses used here as shown
by a nadir weight loss of almost 7 % on day 3 of the study
(1 day after the last dose of Irinophore C™) and minor, but
reproducible changes noted on necropsy. At the end of these
studies (day 10) animals given irinotecan or Irinophore C™
appeared essentially normal. Importantly, the reduction of GI
toxicity that occurred when irinotecan was given as the
Irinophore C™ nanoparticle also occurred when given in
combination with 5-FU. Data from our lab has shown in
numerous cancer models that Irinophore C™ is much more
efficacious then irinotecan, even when the Irinophore C™ is
given at a dose equal to, or lower than, that of the free drug [7,
9, 10]. On the basis of the data presented, it can now be
suggested that improved therapy should be achieved when
using Irinophore C™ and that the use of Irinophore C™ at
efficacious doses will be associated with little or no GI
toxicity; thus providing a significant advantage over the cur-
rently used clinical formulation.
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